MX2021004917A - Sales cristalinas de un inhibidor de calicreina plasmatica. - Google Patents
Sales cristalinas de un inhibidor de calicreina plasmatica.Info
- Publication number
- MX2021004917A MX2021004917A MX2021004917A MX2021004917A MX2021004917A MX 2021004917 A MX2021004917 A MX 2021004917A MX 2021004917 A MX2021004917 A MX 2021004917A MX 2021004917 A MX2021004917 A MX 2021004917A MX 2021004917 A MX2021004917 A MX 2021004917A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline salts
- plasma kallikrein
- kallikrein inhibitor
- methods
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754983P | 2018-11-02 | 2018-11-02 | |
| PCT/US2019/059385 WO2020092898A1 (en) | 2018-11-02 | 2019-11-01 | Crystalline salts of a plasma kallikrein inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004917A true MX2021004917A (es) | 2021-06-18 |
Family
ID=70457981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004917A MX2021004917A (es) | 2018-11-02 | 2019-11-01 | Sales cristalinas de un inhibidor de calicreina plasmatica. |
Country Status (22)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20221373T1 (hr) | 2014-03-07 | 2023-01-06 | Biocryst Pharmaceuticals, Inc. | Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi |
| UY38438A (es) | 2018-11-02 | 2020-05-29 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| WO2021025969A1 (en) * | 2019-08-02 | 2021-02-11 | Teva Pharmaceuticals International Gmbh | Solid state forms of berotralstat |
| CN116375648A (zh) * | 2023-03-22 | 2023-07-04 | 苏州农平科技发展有限公司 | 贝罗司他中间体的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) * | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| EP1828187A2 (en) | 2004-12-15 | 2007-09-05 | Brystol-Myers Squibb Company | Crystalline forms of a factor xa inhibitor |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| EP2051707B1 (en) | 2006-07-31 | 2013-07-17 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| CN102892763B (zh) * | 2010-05-19 | 2016-03-09 | 桑多斯股份公司 | 泊沙康唑及泊沙康唑中间体的纯化 |
| JP5808818B2 (ja) | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| GB201212081D0 (en) * | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
| HRP20221373T1 (hr) * | 2014-03-07 | 2023-01-06 | Biocryst Pharmaceuticals, Inc. | Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi |
| FI4019022T3 (fi) | 2015-10-01 | 2024-04-19 | Biocryst Pharm Inc | Ihmisen plasman kallikreiinin estäjiä |
| UY38438A (es) | 2018-11-02 | 2020-05-29 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| EP4010320A4 (en) | 2019-08-06 | 2023-08-16 | Biocryst Pharmaceuticals, Inc. | Process-scale synthesis of a plasma kallikrein inhibitor |
-
2019
- 2019-10-31 UY UY0001038438A patent/UY38438A/es not_active Application Discontinuation
- 2019-10-31 AR ARP190103187A patent/AR116951A1/es unknown
- 2019-11-01 MA MA054087A patent/MA54087A/fr unknown
- 2019-11-01 EA EA202191192A patent/EA202191192A1/ru unknown
- 2019-11-01 WO PCT/US2019/059385 patent/WO2020092898A1/en not_active Ceased
- 2019-11-01 EP EP19877809.4A patent/EP3873463A4/en active Pending
- 2019-11-01 KR KR1020217013734A patent/KR102810837B1/ko active Active
- 2019-11-01 PE PE2021000587A patent/PE20211280A1/es unknown
- 2019-11-01 IL IL322896A patent/IL322896A/en unknown
- 2019-11-01 PY PY201901991831A patent/PY1991831A/es unknown
- 2019-11-01 AU AU2019374115A patent/AU2019374115B8/en active Active
- 2019-11-01 BR BR112021008249-2A patent/BR112021008249A2/pt unknown
- 2019-11-01 CN CN201980072995.3A patent/CN112969458A/zh active Pending
- 2019-11-01 TW TW108139655A patent/TW202031255A/zh unknown
- 2019-11-01 US US16/671,649 patent/US10662160B1/en active Active
- 2019-11-01 CA CA3117123A patent/CA3117123A1/en active Pending
- 2019-11-01 MX MX2021004917A patent/MX2021004917A/es unknown
- 2019-11-01 JP JP2021522086A patent/JP2022505670A/ja active Pending
- 2019-11-01 SG SG11202103804TA patent/SG11202103804TA/en unknown
-
2020
- 2020-02-06 US US16/784,016 patent/US11117867B2/en active Active
-
2021
- 2021-04-20 IL IL282454A patent/IL282454A/en unknown
- 2021-04-21 PH PH12021550883A patent/PH12021550883A1/en unknown
- 2021-04-27 CL CL2021001094A patent/CL2021001094A1/es unknown
- 2021-05-31 CO CONC2021/0007172A patent/CO2021007172A2/es unknown
- 2021-09-02 US US17/465,181 patent/US11618733B2/en active Active
-
2023
- 2023-03-10 US US18/120,073 patent/US12344585B2/en active Active
-
2024
- 2024-05-27 JP JP2024085295A patent/JP2024109860A/ja active Pending
-
2025
- 2025-05-30 US US19/224,669 patent/US20250388545A1/en active Pending
- 2025-08-28 US US19/312,786 patent/US12545647B2/en active Active
- 2025-08-28 US US19/312,755 patent/US12545646B2/en active Active
- 2025-08-28 US US19/313,010 patent/US12590068B2/en active Active
- 2025-08-28 US US19/312,656 patent/US12552750B2/en active Active
- 2025-08-28 US US19/313,046 patent/US12590069B2/en active Active
- 2025-08-28 US US19/312,645 patent/US12545645B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018008759A2 (es) | Inhibidores de mcl-1 y métodos de uso de los mismos | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| ECSP18040250A (es) | Composiciones y métodos para inhibir la actividad arginasa | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| UY37710A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| CO2021007172A2 (es) | Sales cristalinas de un inhibidor de calicreína plasmática | |
| CL2020003219A1 (es) | Compuestos | |
| CO2020000527A2 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp | |
| UY38837A (es) | Proceso de elaboración de moduladores de cftr | |
| MX2021004593A (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. | |
| SV2018005633A (es) | Derivados de heteroarilo como inhibidores de parp | |
| MX2019003887A (es) | Compuestos, dispositivos y usos de los mismos. | |
| MX2019001581A (es) | Inhibidores de ssao de aminopirimidina. | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| UY36649A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| MX380394B (es) | Compuesto novedoso de bifenilo o una sal del mismo. | |
| BR112016024057A2 (pt) | inibidores de quinases heterocíclicos | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| UY36648A (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
| MX2017013797A (es) | Inhibidor de janus quinasa. | |
| UY36151A (es) | ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?. | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| CL2021001461A1 (es) | Moduladores de trex1 | |
| MX2017013875A (es) | Ciertos inhibidores de la proteína quinasa. |